Opens in a new tab

Edwards Lifesciences v Meril (CFI, 17 October 2025)

Date17 October 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionGeneric Order
Case number(s)UPC_CFI_404/2025;UPC_CFI_405/2025
Registry referenceUPC_CFI_404/2025and · UPC_CFI_405/2025
PartiesEdwards Lifesciences Corporation v. Meril GmbH a.o.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By decision of 17 October 2025 (UPC_CFI_404/2025 and UPC_CFI_405/2025, EP 3 669 828), the judge-rapporteur of the Munich Local Division ordered Meril GmbH, Meril Life Sciences and Meril Italy to pay Edwards Lifesciences EUR 771,649.56 in costs within 20 days, in the joined infringement action and counterclaim. Only a small share of the travel expenses remained in dispute. The decision takes a flexible approach to reviewing representation costs, expressly departing from an order of the Brussels Local Division.

Question

Are travel costs relating to several representatives, in-person meetings, taxis and breakfasts reasonable and proportionate costs recoverable under Art. 69(1) UPCA?

Decision

Yes. Cost proceedings are summary in nature and the judge-rapporteur has broad discretion over procedure, whether costs were incurred and whether they are reasonable and proportionate (section II.1, Rule 156.2 RoP). Neither the UPCA nor the Rules limit the number of representatives or firms acting for a party. Each one’s involvement and in-person meetings are reasonable where the representative considers them necessary, as evidence is hard to produce (section II.2.a). As the disputed amount is a small percentage of the ceiling and of representation costs, the court may award it without detailed review. Taxis and ride-hailing are justified, since representatives can work while travelling (section II.2.b). Edwards having withdrawn certain items (meals, laundry, one representative’s travel), the balance is awarded. The decision has no numbered paragraphs.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 69(1) and 82
Statute of the Court
Art. 37(2)
Rules of Procedure
Rules 151, 156, 157, 262.2 and 262.3
Case law cited
Court of Appeal, UPC_CoA_618/2024 (paragraph 10), Brussels Local Division, 25 July 2025 (UPC_CFI_131/2025), from which the order departs, Edwards Lifesciences v Meril, 4 April 2025 (Munich Local Division, decision ordering the defendants to bear the costs)

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Court fees and costs (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_404/2025 official number
  • UPC_CFI_405/2025 official number

Follow these proceedings

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Generic Order
Outcome (Dhenne Avocats summary)
Les défenderesses Meril doivent payer à Edwards 771 649,56 euros de frais sous 20 jours, les frais de déplacement contestés étant jugés raisonnables et proportionnés.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 669 828
Prosthetic heart valve
recorded proprietor: Edwards Lifesciences Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 11 other decision(s): Edwards Lifesciences v Meril (CFI, 4 April 2025) · Edwards Lifesciences v Meril (CFI, 12 August 2026) · Edwards Lifesciences v Meril (CFI, 26 June 2026) · Edwards Lifesciences v Meril (CFI, 3 June 2025) · Edwards Lifesciences v Meril (CFI, 14 April 2025) · Edwards Lifesciences v Meril (CFI, ORD_60824/2024, 9 April 2025) · Edwards Lifesciences v Meril (CFI, 5 February 2025) · Edwards Lifesciences v Meril (CFI, 20 December 2024)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.